Mid Pharma

Text search

Sort by Default

Display 15 Products per page

Company Analysis: Lundbeck

€2,825.10

PharmaVitae explores Lundbeck’s prescription pharmaceutical performance and outlook over 2017–27. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Gilead

€2,825.10

PharmaVitae explores Gilead’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: BioMarin

€2,825.10

PharmaVitae explores BioMarin’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Biogen

€2,825.10

PharmaVitae explores Biogen’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis: Ionis Pharmaceuticals

€2,825.10

PharmaVitae explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: Seagen

€2,825.10

PharmaVitae explores Seattle Genetics’ prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2021
Find out more
Company Analysis: UCB

€2,825.10

PharmaVitae explores UCB’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts
January 25, 2021
Find out more
Company Analysis: Incyte

€2,825.10

PharmaVitae explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
January 25, 2021
Find out more
Company Analysis: GlaxoSmithKline

€2,825.10

PharmaVitae explores GlaxoSmithKline’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts. The full company profile encompasses analysis on corporate strategy, portfolio analysis, pipeline potential, and financial performance.
January 25, 2021
Find out more
Company Analysis : AbbVie

€2,825.10

PharmaVitae explores AbbVie’s prescription pharmaceutical performance and outlook over 2019–29.
July 15, 2020
Find out more
Company Analysis: Merck KGaA

€2,825.10

PharmaVitae explores Merck KGaA’s prescription pharmaceutical performance and outlook over 2019–29. PharmaVitae analyses include quarterly earnings coverage and provide timely updates to company product forecasts.
January 25, 2020
Find out more
Allergan

€2,825.10

PharmaVitae explores Allergan’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 10, 2018
Find out more
Celgene

€2,825.10

PharmaVitae explores Celgene’s prescription pharmaceutical performance and outlook, encompassing corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2017–27.
October 8, 2018
Find out more
Acorda Company Analysis

€2,825.10

PharmaVitae explores Acorda’s prescription pharmaceutical performance and outlook over 2017–27.
February 9, 2018
Find out more
Actelion

€2,825.10

Analysis of Actelion’s prescription pharmaceutical sales encompassing global corporate strategy, marketed portfolio, pipeline potential, and financial performance over 2015–25.
November 1, 2016
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *